Westfield Capital Management
JAZZ icon

Westfield Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Westfield Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,143,835
Closed -$142M – 265
2018
Q4 		$142M Buy
1,143,835
+31,100
+3% +$4.61M 1.21% 17
2018
Q3 		$187M Buy
1,112,735
+228,774
+26% +$39.3M 1.31% 15
2018
Q2 		$152M Sell
883,961
-319,444
-27% -$52.2M 1.14% 17
2018
Q1 		$182M Sell
1,203,405
-27,167
-2% -$3.99M 1.4% 8
2017
Q4 		$166M Sell
1,230,572
-207,909
-14% -$28.8M 1.27% 11
2017
Q3 		$210M Buy
1,438,481
+115,217
+9% +$17.4M 1.62% 5
2017
Q2 		$206M Sell
1,323,264
-53,950
-4% -$8.25M 1.75% 3
2017
Q1 		$200M Buy
1,377,214
+117,825
+9% +$15.3M 1.72% 3
2016
Q4 		$137M Sell
1,259,389
-378,548
-23% -$42.2M 1.2% 15
2016
Q3 		$199M Sell
1,637,937
-146,825
-8% -$19.8M 1.61% 4
2016
Q2 		$252M Sell
1,784,762
-254,527
-12% -$37.5M 2.08% 2
2016
Q1 		$266M Sell
2,039,289
-447,999
-18% -$55.8M 2.03% 2
2015
Q4 		$350M Buy
2,487,288
+188,562
+8% +$26.1M 2.35% 2
2015
Q3 		$305M Sell
2,298,726
-62,732
-3% -$10.8M 2.16% 4
2015
Q2 		$416M Buy
2,361,458
+29,081
+1% +$5.22M 2.54% 2
2015
Q1 		$403M Buy
2,332,377
+399,081
+21% +$68.5M 2.32% 2
2014
Q4 		$317M Sell
1,933,296
-63,063
-3% -$10.5M 1.86% 4
2014
Q3 		$321M Buy
1,996,359
+101,638
+5% +$15.6M 1.96% 4
2014
Q2 		$279M Buy
1,894,721
+384,791
+25% +$53.4M 1.66% 5
2014
Q1 		$209M Buy
1,509,930
+1,271,735
+534% +$191M 1.25% 8
2013
Q4 		$30.1M Buy
+238,195
New +$24.6M 0.18% 163

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Westfield Capital Management's JAZZ Position: Q1 2019 in Review

Westfield Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 1,143,835 shares — an estimated $142M sold.

Westfield Capital Management first reported a position in JAZZ in Q4 2013 and held it in 21 quarters. The position peaked at $416M in Q2 2015. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

  • Westfield Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Westfield Capital Management sold 1,143,835 Jazz Pharmaceuticals shares in Q1 2019, an estimated $142M.
  • Westfield Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 21 quarters.
  • Westfield Capital Management's Jazz Pharmaceuticals position peaked at $416M in Q2 2015.
  • 427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Westfield Capital Management's 13F filing for Q1 2019, filed 14 May 2019.